ResMed experienced notable upward momentum driven primarily by a high-profile analyst upgrade. RBC Capital Markets raised its rating on the medical device maker to Outperform from Sector Perform while lifting its price target. Analysts highlighted an undemanding valuation following recent price adjustments, noting that market pricing reflects overly pessimistic assumptions regarding long-term competitive dynamics. The positive rating adjustment acted as an immediate catalyst, boosting buying interest and instilling renewed confidence among institutional investors.

Fueling the constructive sentiment is ResMed’s sharpened focus on capital return and portfolio optimization. The…